Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study

This publication has 21 references indexed in Scilit:

• CD19-Targeting CAR T Cells for Myositis and Interstitial Lung Disease Associated With Antisynthetase Syndrome
  JAMA, 2023
• Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial
  The Lancet Rheumatology, 2021
• B Cell Depletion Inhibits Fibrosis via Suppression of Profibrotic Macrophage Differentiation in a Mouse Model of Systemic Sclerosis
  Arthritis & Rheumatology, 2021
• B cells in systemic sclerosis: from pathophysiology to treatment
  Clinical Rheumatology, 2021
• Efficacy and safety of rituximab on lung and skin involvement in systemic sclerosis: a systematic review and metaanalysis
  Clinical Rheumatology, 2021
• Altered B lymphocyte homeostasis and functions in systemic sclerosis
  Autoimmunity Reviews, 2018
• Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia
  Blood Cancer Journal, 2014
• B cell infiltration in systemic sclerosis–associated interstitial lung disease
  Arthritis & Rheumatism, 2007
• Elevated serum BAFF levels in patients with systemic sclerosis: Enhanced BAFF signaling in systemic sclerosis B lymphocytes
  Arthritis & Rheumatism, 2005
• Altered blood B lymphocyte homeostasis in systemic sclerosis: Expanded naive B cells and diminished but activated memory B cells
  Arthritis & Rheumatism, 2004